ImmunOs ImmunOs ImmunOs

ImmunOs

Immuno-oncology for hematological and solid tumors

Established in 2014 as a spinoff from the Universities of Zürich and Basel, ImmunOs Therapeutics is a biotechnology company at clinical stage. ImmunOs has developed a proprietary technology platform to research a novel class of biologic therapeutics for the treatment of cancer and autoimmune diseases. ImmunOs' lead programme, IOS-1002, has been in clinical development since 2023.

Life Sciences

Visit website

Investment  details

Entry

2022

Staff

Location

Switzerland

Our goal with ImmunOs is to develop novel therapeutics based on our proprietary human leukocyte antigen (HLA)-based platform to create a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases to improve the lives of patients with serious diseases.

Sean R. Smith

CEO

Partnership Gimv Partnership Gimv Partnership Gimv

Partnership Gimv

ImmunOs' approach to new cancer drugs is based on insights into how the human body controls the immune system and translates these into new treatment approaches for the benefit of patients. This epitomises the mission of Gimv's life sciences platform: to build leading companies that have a lasting impact on patients and society.